CLRB News and Press, Cellectar Biosciences Inc. From 05/06/19

Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma ...

Soleno Therapeutics (NASDAQ: SLNO ) -10% . More news on: Soleno Therapeutics, Inc., Tencent Music Entertainment Group, Cellectar Biosciences, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) is up  40%  premarket on robust volume on the heels of the FDA's Import Alert exemption granted to the Centre for Probe Development and Commercialization (CPDC) related to the company's pediatric IND for lead candidate ...

Altimmune (NASDAQ: ALT ) +44%  on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...

FLORHAM PARK, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Ad...

Cellectar Biosciences (NASDAQ: CLRB ): FY GAAP EPS of -$5.23 misses by $0.70. Cash, cash equivalents and restricted cash of $13.3M Press Release More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

FLORHAM PARK, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ...

Thinly traded nano cap Cellectar Biosciences ( CLRB +7.2% ) is up on more than a 7x surge in volume, albeit on turnover of only 424K shares, in response to new data from a Phase 2 clinical trial, CLOVER-1 , evaluating lead candidate CLR 131 in patients with treatment-resistant B-cell bl...

Company’s lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this study Dosing in multiple tumor types is ongoing; Cellectar intends to report additional data this year FLORHAM PARK, N.J., Feb. 25, 2019 (...

FLORHAM PARK, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, preside...